JP2013514367A5 - - Google Patents

Download PDF

Info

Publication number
JP2013514367A5
JP2013514367A5 JP2012544740A JP2012544740A JP2013514367A5 JP 2013514367 A5 JP2013514367 A5 JP 2013514367A5 JP 2012544740 A JP2012544740 A JP 2012544740A JP 2012544740 A JP2012544740 A JP 2012544740A JP 2013514367 A5 JP2013514367 A5 JP 2013514367A5
Authority
JP
Japan
Prior art keywords
item
salt according
items
ring
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012544740A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013514367A (ja
JP5634526B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/060439 external-priority patent/WO2011084453A1/en
Publication of JP2013514367A publication Critical patent/JP2013514367A/ja
Publication of JP2013514367A5 publication Critical patent/JP2013514367A5/ja
Application granted granted Critical
Publication of JP5634526B2 publication Critical patent/JP5634526B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012544740A 2009-12-15 2010-12-15 代謝性疾患を処置するためのppar温存チアゾリジンジオン塩 Active JP5634526B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28676509P 2009-12-15 2009-12-15
US61/286,765 2009-12-15
PCT/US2010/060439 WO2011084453A1 (en) 2009-12-15 2010-12-15 Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases

Publications (3)

Publication Number Publication Date
JP2013514367A JP2013514367A (ja) 2013-04-25
JP2013514367A5 true JP2013514367A5 (enExample) 2013-06-06
JP5634526B2 JP5634526B2 (ja) 2014-12-03

Family

ID=43501294

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012544740A Active JP5634526B2 (ja) 2009-12-15 2010-12-15 代謝性疾患を処置するためのppar温存チアゾリジンジオン塩

Country Status (16)

Country Link
US (2) US8912335B2 (enExample)
EP (1) EP2513070B1 (enExample)
JP (1) JP5634526B2 (enExample)
KR (3) KR102029611B1 (enExample)
CN (1) CN102753539B (enExample)
AU (1) AU2010340055B2 (enExample)
CA (1) CA2783468C (enExample)
DK (1) DK2513070T3 (enExample)
ES (1) ES2658168T3 (enExample)
HU (1) HUE038042T2 (enExample)
MX (1) MX2012006725A (enExample)
NO (1) NO2513070T3 (enExample)
NZ (1) NZ600390A (enExample)
PL (1) PL2513070T3 (enExample)
RU (1) RU2564661C2 (enExample)
WO (1) WO2011084453A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2513070T3 (en) 2009-12-15 2018-01-22 Cirius Therapeutics Inc PPAR-sparing thiazolidinedione salts for the treatment of metabolic disorders
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG10201705097PA (en) 2012-12-21 2017-07-28 Sanofi Sa Functionalized exendin-4 derivatives
ES2813363T3 (es) * 2013-07-22 2021-03-23 Metabolic Solutions Dev Co Llc Compuestos ahorradores de PPAR para el tratamiento de enfermedades metabólicas
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
US20210038566A1 (en) 2018-02-08 2021-02-11 Enyo Pharma Use of modulators of neet proteins for the treatment of infection
CN111689934B (zh) * 2020-06-24 2022-08-02 郑州大学 14-脱羟-13-脱氢穿心莲内酯-12-磺酸钾的单晶体及制备方法
GB202210503D0 (en) 2022-07-18 2022-08-31 Univ Court Univ Of Glasgow Materials and methods for treatment of chronic myeloid leukemia (CML)

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
WO1985004170A1 (fr) 1984-03-21 1985-09-26 Takeda Chemical Industries, Ltd. Derives de thiazolidinedione, leur procede de preparation et compositions medicinales les contenant
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物,其制备方法和用途
WO1986002073A1 (fr) 1984-10-03 1986-04-10 Takeda Chemical Industries, Ltd. Derives de thiazolidinedione, procede de preparation et composition pharmaceutique les contenant
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5167228A (en) 1987-06-26 1992-12-01 Brigham And Women's Hospital Assessment and modification of endogenous circadian phase and amplitude
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5143930A (en) 1990-02-07 1992-09-01 Sankyo Company, Limited Thiazolidine derivatives with anti-diabetic activity, their preparation and their use
US5356913A (en) 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
SK109993A3 (en) 1991-04-11 1994-12-07 Upjohn Co Thiazolidinedione derivatives producing and use thereof
NO302471B1 (no) 1991-12-26 1998-03-09 Sankyo Co Tiazolidinforbindelser og farmasöytisk preparat
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IL118778A (en) 1995-07-03 1999-07-14 Sankyo Co Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor
US7407978B2 (en) 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
AU776162B2 (en) 1999-04-29 2004-08-26 City Of Hope Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (AGE's)
US6331596B1 (en) 1999-06-28 2001-12-18 Basf Corporation Method of preparing carbamate-functional polymers
CN1171872C (zh) 1999-06-30 2004-10-20 图拉列克股份有限公司 调节PPARγ活性的化合物
WO2001082916A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
EP1353727A2 (en) 2000-12-01 2003-10-22 Novartis AG Combinations of an angiotensin receptor antagonist and an anti-hypertensive drugor a statin, for the treatment of sexual dysfunction
HUP0400091A2 (hu) 2001-04-26 2004-06-28 Léciva, a.s. Eljárás antidiabetikus hatású pioglitazon előállítására
WO2003026586A2 (en) 2001-09-28 2003-04-03 Teva Pharmaceutical Industries Ltd. Pioglitazone hydrochloride
AUPS236902A0 (en) 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
AU2003272072A1 (en) 2002-07-16 2004-02-02 Cadila Healthcare Limited A process to prepare pioglitazone via several intermediates.
US20060083784A1 (en) 2002-08-07 2006-04-20 Smithkline Beecham Corporation Amorphous pharmaceutical compositions
US7230016B2 (en) 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
WO2005021542A2 (en) 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Process for the preparation of pioglitazone
AR047541A1 (es) 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
JP4475983B2 (ja) 2004-03-03 2010-06-09 学校法人日本大学 Bmal1を阻害する方法
BRPI0516219A (pt) 2004-09-28 2008-08-26 Otsuka Pharma Co Ltd composto de carboestirila
PL2001469T3 (pl) 2006-03-16 2012-10-31 Metabolic Solutions Dev Co Llc Analogi tiazolidynodionu
MX356584B (es) 2006-03-16 2018-06-05 Metabolic Solutions Dev Co Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.
EP2001470A2 (en) * 2006-03-16 2008-12-17 Metabolic Solutions Development Company Combination therapies of thiazolidinedione analogues
NZ597381A (en) * 2007-09-14 2013-03-28 Metabolic Solutions Dev Co Llc Thiazolidinedione analogues for the treatment of diabetes and inflammatory diseases
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
ES2399179T3 (es) * 2008-08-07 2013-03-26 Pulmagen Therapeutics (Inflammation) Limited Tratamiento de enfermedad respiratoria
WO2010105048A1 (en) 2009-03-12 2010-09-16 Metabolic Solutions Development Company Thiazolidinedione analogues
WO2011017244A1 (en) 2009-08-05 2011-02-10 Metabolic Solutions Development Company Polymorphs of 5-(4-(2-(5-ethylpyridin-2-yl)-2-oxoethoxy)benzyl)-1,3-thiazolidine-2,4-dione (mitoglitazone)
AU2010340061A1 (en) 2009-12-15 2012-06-21 Metabolic Solutions Development Company, Llc PPAR-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases
CN102753170A (zh) 2009-12-15 2012-10-24 新陈代谢解决方案开发公司 治疗糖尿病及其它代谢性疾病的ppar节制的噻唑烷二酮和组合
DK2513070T3 (en) 2009-12-15 2018-01-22 Cirius Therapeutics Inc PPAR-sparing thiazolidinedione salts for the treatment of metabolic disorders
MX2012006730A (es) 2009-12-15 2012-07-30 Metabolic Solutions Dev Co Llc Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxizoma (ppar) y combinaciones para tratamiento de enfermedades neurodegenerativas y otras enfermedades metabolicas.
AU2011242844A1 (en) 2010-04-21 2012-11-01 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues

Similar Documents

Publication Publication Date Title
JP2013514367A5 (enExample)
JP2012041349A5 (enExample)
JP2016505614A5 (enExample)
RU2012129930A (ru) Соли тиазолидиндиона со сниженным сродством к ppar для лечения нарушений обмена веществ
JP2011513305A5 (enExample)
JP2016503793A5 (enExample)
IN2014CN00794A (enExample)
JP2014525420A5 (enExample)
JP2013544860A5 (enExample)
JP2011522789A5 (enExample)
JP2016006118A5 (enExample)
JP2014532060A5 (enExample)
JP2013544276A5 (enExample)
JP2016040288A5 (enExample)
MX2010002904A (es) N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv).
JP2013540713A5 (enExample)
JP2014508811A5 (enExample)
RU2007139634A (ru) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
JP2011500550A5 (enExample)
CO6251243A2 (es) Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c
JP2012140436A5 (ja) 物質
JP2011516610A5 (enExample)
JP2015504067A5 (enExample)
JP2013544854A5 (enExample)
JP2012512863A5 (enExample)